You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

New Clinical Practice Guidelines for Clostridium difficile Infection

Wilcox, Mark H. MD

Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e3181ee62aa
Clinical Guidelines
Abstract

The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America have recently issued updated evidence-based guidelines on the epidemiology, diagnosis, treatment, and infection control and environmental management of Clostridium difficile infection (CDI) in adults. The guidelines were issued to reflect the marked changes in the epidemiology and manifestations of CDI during the past decade (and since a Society for Healthcare Epidemiology of America guideline on CDI was published in 1995). This review highlights key recommendations from the new guidelines.

Author Information

From the Department of Microbiology, Leeds Teaching Hospitals & University of Leeds, Old Medical School, Leeds General Infirmary, Leeds, UK.

Correspondence to: Mark H. Wilcox, MD, Department of Microbiology, Leeds Teaching Hospitals & University of Leeds, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, UK. E-mail: mark.wilcox@leedsth.nhs.uk.

The author has no funding or conflicts of interest to disclose.

Prof. Wilcox is an advisory board member for Actelion, Astellas, Cerexa, J&J, MSD, Nabriva, Novacta, Optimer, Phico Therapeutics, The Medicines Company, and Viropharma. He is currently a consultant to Cerexa, Pfizer, Photopharmica, Summit, and Wyeth and has research collaborations with Actelion, Novacta, Summit, and The Medicines Company.

© 2010 Lippincott Williams & Wilkins, Inc.